Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Top Page
Lantern Pharma
(NASDAQ:LTRN)
45Neutral
Lantern Pharma (LTRN) vs. S&P 500 (SPY)
Market Cap
$35.81M
Dividend YieldN/A
Average Volume (3M)51.47K
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue GrowthN/A
EPS Growth-31.16%
CountryUS
Employees24
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.42
Shares Outstanding10,784,725
10 Day Avg. Volume77,776
30 Day Avg. Volume51,474
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.41
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue40.34
Enterprise Value/Gross Profit8.78K
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$25.00Price Target Upside653.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Lantern Pharma Business Overview & Revenue Model
Company DescriptionLantern Pharma Inc. (LTRN) is a biotechnology company focused on leveraging artificial intelligence (AI), machine learning, and genomic data to streamline the drug development process in oncology. The company's mission is to improve the efficiency and success rate of cancer drug development by identifying and advancing promising drug candidates. Lantern Pharma operates in the healthcare and biotechnology sectors, developing precision medicine approaches for cancer treatment.
How the Company Makes MoneyLantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its drug candidates, thereby reducing time and cost associated with drug development. Revenue streams include out-licensing partnerships, collaborations with pharmaceutical companies, and potentially, future sales of approved drugs. These partnerships often involve milestone payments, royalties, and shared development costs, which are significant contributors to the company's earnings. As Lantern Pharma advances its drug pipeline and secures additional partnerships, these factors are expected to drive financial growth.
Lantern Pharma Financial Statement Overview
Summary
Lantern Pharma faces significant financial challenges, with zero revenue and increasing operational losses. Despite a strong balance sheet with low debt, the negative cash flow situation raises concerns about long-term viability and the need for additional financing.Income Statement
Lantern Pharma has consistently reported zero revenue, indicating a pre-revenue stage or significant challenges in generating sales. The company's net losses have increased substantially over the years, reflecting mounting operational challenges. The EBIT and EBITDA margins are negative due to high operational expenses without corresponding revenue, undermining profitability prospects.20
Very Negative
Balance Sheet
The company maintains a strong equity position relative to its assets, with a high equity ratio, reflecting financial stability. The debt-to-equity ratio is low, indicating minimal reliance on debt financing, which reduces financial risk. However, the consistent increase in liabilities and decreasing cash reserves could affect future liquidity and operational capacity.60
Neutral
Cash Flow
Lantern Pharma exhibits negative operating and free cash flows, indicating cash burn without revenue inflow. Despite substantial financing inflows in prior years, the inability to generate positive cash flows from operations is concerning. The lack of free cash flow growth highlights potential sustainability challenges.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -174.84K | -154.68K | -97.42K | -3.39K | EBIT |
| -22.22B | -17.88M | -14.43M | -12.59M | -5.91M | EBITDA |
| -20.59M | -15.79M | -14.42M | -12.27M | -5.90M | Net Income Common Stockholders |
| -20.78B | -15.96M | -14.09M | -12.30M | -5.91M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 24.01M | 41.30M | 55.20M | 70.73M | 19.23M | Total Assets |
| 25.57M | 43.65M | 58.84M | 73.95M | 20.36M | Total Debt |
| 243.66K | 234.47K | 52.89K | 204.95K | 108.50K | Net Debt |
| -7.27M | -21.70M | -37.15M | -51.32M | -19.12M | Total Liabilities |
| 4.38M | 2.74M | 2.80M | 2.38M | 660.84K | Stockholders Equity |
| 21.19B | 40.91M | 56.04M | 71.57M | 19.70M |
| Cash Flow | Free Cash Flow | |||
| -17.83M | -14.37M | -12.80M | -10.61M | -5.67M | Operating Cash Flow |
| -17.81M | -14.35M | -12.77M | -10.59M | -5.65M | Investing Cash Flow |
| 3.37M | -930.21K | 179.27K | -19.53M | -16.14K | Financing Cash Flow |
| 66.71K | -500.00K | ― | 63.42M | 23.66M |
Lantern Pharma Technical Analysis
Negative
3.32
Price Trends
3.58
Positive
3.88
Negative
3.77
Negative
Market Momentum
0.06
Positive
47.66
Neutral
32.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Negative. The current price of 3.32 is below the 20-day moving average (MA) of 3.74, below the 50-day MA of 3.58, and below the 200-day MA of 3.77, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 47.66 is Neutral, neither overbought nor oversold. The STOCH value of 32.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LTRN.
Lantern Pharma Risk Analysis
Lantern Pharma disclosed 72 risk factors in its most recent earnings report. Lantern Pharma reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lantern Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.19B | 3.04 | -44.64% | 2.82% | 16.45% | -0.53% | |
45 Neutral | $35.81M | ― | -75.66% | ― | ― | -31.16% | |
40 Underperform | $50.26M | ― | -82.81% | ― | -92.95% | -50.02% | |
39 Underperform | $85.36M | ― | -83.71% | ― | ― | ― | |
38 Underperform | $50.15M | ― | 0.00% | ― | ― | ― | |
36 Underperform | $51.68M | ― | -130.27% | ― | ― | 43.64% | |
34 Underperform | $36.51M | ― | -49.32% | ― | ― | 38.98% |
* Healthcare Sector Average
Performance Comparison
LTRN
Lantern Pharma
3.58
-2.24
-38.49%
FBRX
Forte Biosciences
7.50
-7.68
-50.59%
APLT
Applied Therapeutics
0.46
-3.74
-89.05%
HOWL
Werewolf Therapeutics
1.12
-3.66
-76.57%
ANTX
AN2 Therapeutics, Inc.
1.19
-1.04
-46.64%
OKYO
OKYO Pharma Limited Sponsored ADR
1.60
0.11
7.38%
Lantern Pharma Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: -18.23%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call presented significant advancements in the clinical pipeline and AI platform, highlighting strategic initiatives to maximize shareholder value and financial discipline. However, the need for additional funding and potential risks associated with AI implementation were noted as challenges.Q1-2025 Updates
Positive Updates
Advancement in Clinical Pipeline
The Phase 1a trial for LP-184 has progressed well, with enrollment now through cohort 12. The trial is expected to complete enrollment with 62 to 65 patients by June 2025, and early indications of clinical activity at higher dose levels align with preliminary pharmacokinetic data.
AI Platform Expansion
The radar AI platform expanded to over 200 billion oncology-focused data points. The platform is being opened to the scientific community on a module-by-module basis, starting with a freemium approach to drive collaborations and economic opportunities.
Financial Discipline
Lantern Pharma ended the quarter with approximately $19.7 million in cash, cash equivalents, and marketable securities, providing an expected operating runway through at least mid-May 2026. The quarterly net loss decreased to approximately $4.5 million from $5.4 million in the same period last year.
Strategic Initiatives for Shareholder Value
Lantern Pharma is engaging in discussions for potential partnerships, including licensing agreements, technology partnerships, and co-development opportunities to accelerate the pipeline.
Innovative AI Modules
Introduction of an AI-powered module to improve antibody-drug conjugate development, capable of reducing timelines by 30%-50% and preclinical costs by up to two-thirds.
Negative Updates
Need for Additional Funding
Despite a strong cash position, the company anticipates the need for additional funding in the near future to support ongoing operations and growth initiatives.
Risks Associated with AI Implementation
Acknowledgement of the potential risks associated with implementing AI in drug development and regulatory processes, requiring careful management and evaluation.
Company Guidance
During the First Quarter 2025 Earnings Call, Lantern Pharma provided extensive guidance on its strategic initiatives and financial metrics. The company highlighted significant progress in its clinical pipeline, particularly with LP-184, which has advanced to cohort 12 in its Phase 1a trial with an expected enrollment of 62 to 65 patients by June 2025. This trial aims to address various solid tumors, and early indications show clinical activity at higher doses. Lantern also emphasized the dual fast track designations for LP-184 in glioblastoma and triple-negative breast cancer, presenting major market opportunities. The company reported a net loss of $4.5 million for Q1 2025, a decrease from $5.4 million in the previous year, reflecting operational efficiency improvements, while maintaining a cash position of $19.7 million. Additionally, Lantern plans to commercialize its radar AI platform, now expanded to 200 billion oncology-focused data points, offering new revenue streams through a freemium model. With strategic partnerships and disciplined capital management, the company projects a financial runway until mid-May 2026.Lantern Pharma Corporate Events
Business Operations and StrategyFinancial Disclosures
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress
Positive
Mar 27, 2025
On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.